When Will Generic Semaglutide Be Available in the US?
Generic semaglutide is not expected in US pharmacies until 2032, with patent loss in Europe and the US placed in the 2031–32 window. India lost protection in March 2026 and generics are on sale there now; Canada and Brazil have approved products, with launches pending.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Generic semaglutide is not expected in US pharmacies until 2032. CNBC reports that the US, Novo’s largest market by far, is protected from generic competition until 2032 [8], and Fierce Pharma puts semaglutide’s patent loss in Europe and the United States in the 2031–32 timeframe [1]. The reason generics exist elsewhere is simple: semaglutide’s patents were set to expire in India, China, Brazil, Türkiye and Canada during 2026, per C&EN’s December 2025 reporting [2], and expiries have since been confirmed in India, Brazil and Canada, opening those markets to copycat versions while the US wall holds [1][9][3].
The US delay is not an accident of timing but a function of intellectual property. BMO Capital Markets analyst Evan Seigerman said strong US intellectual property protections should prevent meaningful spillover from Canadian generic entry, even as Ozempic faces growing competition from drugs such as Mounjaro [6]. Ozempic was approved by the FDA in 2017 and Wegovy in 2021, and the two drugs generated $26 billion in revenue for Novo Nordisk in 2024 [2].
Why is generic semaglutide already sold in other countries?
Patents on the same drug expire at different times in different countries, depending on what each patent office granted and whether maintenance fees were paid. C&EN reported in December 2025 that semaglutide would lose protection in 2026 in India (March), China (March), Brazil (March), Türkiye and Canada [2]. India’s core patent expired on March 20, 2026, and generic makers launched the very next day, on March 21, 2026 [1][7]. Brazil’s Ozempic patent expired in March 2026 [9].
Canada’s path was unusual. The core semaglutide patent lapsed there after missed maintenance fee payments, and data exclusivity expired on January 4, 2026 [3]. In Europe and the United States, semaglutide’s patent loss falls in the 2031–32 timeframe [1].
The scale is large. IQVIA estimates that about one-third of the world’s adults with obesity live in the markets hit by this patent cliff [3][2].
Which companies are lined up for the US market?
The US queue is already forming behind the patent wall. Apotex received the first US FDA tentative approval for a generic semaglutide ANDA, reported on April 10, 2026 [5]. A tentative approval does not allow sales now — it positions Apotex to be among the first to launch generic Ozempic in the US after Novo Nordisk’s exclusivity and patents expire [5].
There is also precedent for negotiated entry. Novo and Mylan previously inked a patent settlement in the Ozempic case [1]. And Aspen Pharmacare has laid out a launch sequence that puts Canada and emerging markets first, followed by Mexico, New Zealand, Europe and then the US [3].
What is happening in Canada?
Health Canada authorized the first generic semaglutide injection on April 28, 2026, made by Dr. Reddy’s Laboratories — the first generic semaglutide approved in the G7 [4][6]. It is a generic version of Ozempic, indicated for the once-weekly treatment of adults with type 2 diabetes to manage blood sugar [4]. The approval covers 2 mg/pen and 4 mg/pen formulations (1.34 mg/mL) [5]. No launch date has been announced, though Dr. Reddy’s has said its launch plans are underway [5].
Days later, on May 1, 2026, Apotex announced Health Canada approval of Apo-Semaglutide Injection, in prefilled pens covering 0.25 mg or 0.5 mg doses (2 mg of semaglutide, 0.68 mg/mL) and 1 mg doses (4 mg, 1.34 mg/mL). Apotex developed the product through a partnership with Orbicular Pharmaceutical Technologies, headquartered in India [5].
More approvals are coming. As of April 28, 2026, Health Canada was reviewing eight other generic semaglutide submissions [4][6]; in January 2026, nine applications were under review with no timeline given [3]. Named pending filers include Teva, Aspen Pharmacare, Taro Pharmaceuticals and Sandoz [5]. On timing, the sources differ: Reuters reports Sandoz plans to launch its Canadian generic by June 2026 [6], while Sandoz CEO Richard Saynor said in January that he now expects the Canadian generic market to take shape in the third quarter of 2026, after the regulator told both Sandoz and Dr. Reddy’s to provide more data to meet regulatory standards [3]. Sandoz describes Canada as the world’s second-largest semaglutide market [3]. Health Canada completed its review of Dr. Reddy’s submission within its 180-day target for generic submissions [4].
On price, many Canadian generics are 45% to 90% cheaper than brand-name versions [4][6]. Canadian policy drives list-price discounts of about 65% once three generic competitors are on the market [3]. Analysts cited by Bloomberg expect a price war that could push monthly costs to around $15 in some countries as volumes scale [3].
How cheap are the generics in India?
India saw the fastest and deepest price collapse. More than 40 generic makers were expected to launch, with more than 50 brands expected in the coming months [1][8]. Day-one launchers included Dr. Reddy’s (Obeda), Zydus (Semaglyn, Mashema, Alterme), Alkem (Semasize, Obesema, Hepaglide), Sun Pharma (Noveltreat, Sematrinity), Glenmark (GLIPIQ) and Natco [7][1].
| Company (product) | Format | Price |
|---|---|---|
| Natco | Multi-dose vials | 1,290–1,750 rupees/month ($13.79–$18.71); pens 4,000–4,500 rupees ($42.77–$48.12) [1] |
| Natco (CNBC figure) | Vials | 1,250 rupees/month [8] |
| Alkem (Semasize, Obesema, Hepaglide) | Prefilled pens | From 1,800 rupees/month (~450 rupees/week) [7] |
| Zydus (Semaglyn, Mashema, Alterme) | Reusable multi-dose pen | ~2,200 rupees/month [7] |
| Dr. Reddy’s (Obeda) | Prefilled disposable pen | ~4,200 rupees/month [7][8] |
| Sun Pharma (Noveltreat) | Prefilled pen | ~900–2,000 rupees/week [7] |
| Sun Pharma (Sematrinity) | Multi-dose pen | ~750–1,300 rupees/week [7] |
| Sun Pharma (company-level figure) | Weekly injection | As low as 750 rupees ($8) per week, about 3,400 rupees/month [8] |
| Glenmark (GLIPIQ) | Vials | ~325–440 rupees/week [7] |
For comparison, Novo’s branded Ozempic sold in India at 8,800 to 11,175 rupees ($94–$119) per month and Wegovy at up to 16,400 rupees ($175) per month [1]. Sun Pharma and Dr. Reddy’s launched at roughly 50% below Novo’s original prices, while smaller domestic makers such as Natco and Alkem offered discounts of nearly 80% [8]. Vials are consistently cheaper than pen devices across the Indian launches [1][7].
Novo has fought back. It cut the price of Wegovy in India by 37% from its launch price in December 2025, before the patent expired [8], and is selling second brands there: Wegovy as Poviztra through Emcure Pharma and Ozempic as Extensior with Abbott India [8]. Dr. Reddy’s, meanwhile, is targeting 12 million semaglutide pens in its first year across all markets and plans to expand to Canada, Turkey and Brazil in 2026 [8].
What about Brazil and China?
Brazil’s regulator Anvisa approved EMS’s Ozivy, the country’s first semaglutide injector pen, on May 26, 2026 [9]. The drug will be made at an EMS plant in São Paulo state with capacity for up to 40 million pens per year. It can be marketed only after Brazil’s medicine pricing chamber approves a price cap, and inclusion in the public healthcare system SUS requires Health Ministry approval [9]. Anvisa is reviewing five other synthetic semaglutide applications plus one biological version, and EMS rival Hypera had previously said it also planned to launch its generic semaglutide in 2026 [9].
In China, C&EN reported in December 2025 that the patent was set to expire in March 2026, and that 17 candidates had reached Phase 3 clinical trials or the premarket application stage as of that December [2]. Chinese government procurement has historically cut prices of other drugs by as much as 90% once generics arrive [3].
Can US patients buy these foreign generics?
These products are not authorized for sale in the United States. Approvals from Health Canada, India’s DCGI or Brazil’s Anvisa are not FDA approvals [4][9][7]. There is concern in the industry that Indian-made GLP-1s could leak into markets where the drug is still patent-protected [8], and Novo has pursued legal action against sellers of unauthorized versions in gray markets, with mixed results [3]. IQVIA has warned that as more manufacturers enter, the dangers of counterfeiting and substandard quality are likely to multiply [3].
What does a generic semaglutide approval actually require?
A generic approval is a specific regulatory pathway, and it is not automatic. Health Canada authorized its first generic semaglutide only after a thorough review of evidence provided by the company demonstrated that the drug meets criteria for safety, efficacy and quality for generic drugs [4]. Health Canada describes generic semaglutide products as complex synthetic products that are pharmaceutically equivalent to the brand-name drug, and its review ensures that differences between these products do not affect safety, efficacy or quality [4].
The manufacturing is also distinctive. Novo makes semaglutide using recombinant yeast fermentation plus solid-phase synthesis, while generic versions are likely made by fully synthetic routes [2].
Will generic Ozempic be cheaper in the US, and by how much?
Discounts in the markets that lost patent protection have been steep, and the size of the discount depends on how many competitors launch. A consultant quoted by C&EN estimated that generic entry in those off-patent markets could lower the cost by 80% in some cases [2]. India’s deep discounts came from a crowded field: more than 40 generic makers were expected to launch [1], and at least five domestic drugmakers undercut the original price by up to 80% on day one [8]. Canada’s roughly 65% list-price cut requires three competitors on the market [3].
Several factors slow the drop. Peptide drugs need stringent quality control, and pen devices and cold-chain distribution add manufacturing complexity [8]. Generic makers have historically struggled to scale production enough to displace Novo — the insulin market is the precedent [8]. A Systematix analyst said Novo could keep a large share of the market even at a 15%–20% premium over generics [8].
What changes in the US before generics arrive?
Prices are already moving. A November 2025 deal between the Trump administration and Eli Lilly and Novo Nordisk cut GLP-1 prices in the US [8]. Novo warned in February that 2026 sales could decline 5% to 13% [8].
Competition is eroding Novo’s position: Lilly’s Mounjaro and Zepbound continue to gain market share [6], and Mounjaro still has about a decade of patent life left [3]. In 2024, Novo generated $26 billion from Wegovy and Ozempic, while Lilly’s Mounjaro and Zepbound brought in nearly $16 billion [2]. Novo has responded with a new CEO, price cuts, a Wegovy pill launch, and pipeline products such as CagriSema and amycretin [3].
By the time US patents expire in the 2031–32 window, the competitive landscape will likely be vastly different, with several more products on the market [1].
Sources
- Fierce Pharma. Generic versions of Novo’s semaglutide launch today in India. March 20, 2026.
- Chemical & Engineering News. Looming GLP-1 drug patent expirations draw generics firms. December 9, 2025.
- Benefits and Pensions Monitor. Ozempic generics set to test Canada’s drug budgets. January 16, 2026.
- Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. April 28, 2026.
- Pearce IP. First Generic Ozempic (Semaglutide) Approved in Canada for Dr Reddy’s & Apotex. April 29, 2026.
- Reuters. Canada approves first generic version of Ozempic amid rising GLP-1 competition. April 28, 2026.
- Pearce IP. Generic Semaglutide Launches in India, including by Dr Reddy’s, Zydus, Alkem, Sun Pharma & Glenmark. March 21, 2026.
- CNBC. India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top. March 23, 2026.
- Reuters. Brazil approves first generic semaglutide pen after Ozempic patent expiry. May 26, 2026.
- VCBeat Health. Semaglutide Patent Expires Today, 12 Fastest Chinese-Made Needles! March 20, 2026.
- US Food and Drug Administration. Personal Importation.
- BBC News. Why Canadians can now get cheaper generic Ozempic - and Americans can’t. June 3, 2026.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
- Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
- Health Canada. Canada approves first generic semaglutide for weight loss. June 29, 2026.
Frequently asked questions
What year will generic semaglutide be available in US pharmacies?
Not before 2032. CNBC reports the US, Novo's largest market by far, is protected from generic competition until 2032, and Fierce Pharma places semaglutide's patent loss in Europe and the US in the 2031–32 timeframe. Apotex's FDA tentative approval positions it to launch only after that protection ends.
Will generic Ozempic and generic Wegovy arrive at the same time?
The first approvals split by indication. Health Canada's April 28, 2026 approval of Dr. Reddy's product, a generic version of Ozempic, covers once-weekly treatment of adults with type 2 diabetes. In India, day-one generics from Zydus, Alkem and Sun Pharma (Noveltreat) carry approvals for obesity or chronic weight management.
Is it legal to import generic semaglutide from Canada or India?
These products are not authorized for US sale. Approvals from Health Canada, India's DCGI or Brazil's Anvisa are not FDA approvals. Novo has pursued legal action against sellers of unauthorized versions in gray markets, with mixed results, and IQVIA has warned that counterfeiting and substandard-quality dangers multiply as more manufacturers enter.
Which companies have US approval applications for generic semaglutide?
Apotex received the first US FDA tentative approval for a generic semaglutide ANDA, reported April 10, 2026. Aspen Pharmacare has announced a launch sequence ending in the US after Canada, emerging markets, Mexico, New Zealand and Europe. Teva, Aspen, Taro and Sandoz have generic semaglutide applications under review in Canada.
Does an FDA 'tentative approval' mean the product can be sold now?
No. Apotex's tentative approval gives it an opportunity to be one of the first to launch generic Ozempic in the US following expiry of Novo Nordisk's exclusivity and patents, which reporting places in the 2031–32 window. Until then, the product cannot be marketed in the US.
Why did Canada get generic semaglutide years before the US?
Canada's core semaglutide patent lapsed after missed maintenance fee payments, and data exclusivity expired on January 4, 2026. The US did not have the same early lapse, and analysts say strong US intellectual property protections should prevent spillover from Canadian generics.
How much cheaper is generic semaglutide in India versus the brand?
Day-one launchers undercut Novo's original prices by up to 80%. Natco's vials run 1,290–1,750 rupees ($13.79–$18.71) per month, versus branded Ozempic at 8,800–11,175 rupees and Wegovy at up to 16,400 rupees per month. Sun Pharma and Dr. Reddy's launched at roughly 50% below Novo's prices.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.